-Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB) patient cohorts-In the first clinical data presentation from our NASH program, preliminary data on multiple ascending doses of ALG-055009 in subjects with hyperlipidemia demonstrated favorable pharmacokinetics, safety, and anti-lipid activity-Presentations include nonclinical data from 2 other CHB programs SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is presenting two posters showcasing preliminary Phase 1 data from its capsid assembly modulator (CAM) program in CHB and its thyroid hormone receptor-beta (THR-b) agonist in nonalcoholic steatohepatitis (NASH) at the European Association for the Study of the Liver Digital International Liver Congress™ 2022 (EASL ILC 2022). ILC 2022 is being held on June 22 - 26 at the ExCeL London Exhibition Centre in London, UK. The company is also presenting nonclinical data from two other drug classes within Aligos’ CHB portfolio: small interfering RNA (siRNA) and a small molecule PD-L1 inhibitor. The posters will be available on the “Scientific Presentation and Publications” page in the “Presentations” section of Aligos’ website at www.aligos.com. “We are pleased to continue demonstrating progress from across our chronic hepatitis B portfolio including small-molecule capsid assembly modulators, small interfering RNA molecules and small-molecule PD-L1 inhibitors. Our team is also proud to announce the first clinical data from our THR-b agonist in NASH,” said Lawrence Blatt, Ph.D., MBA, Chairman and CEO of Aligos. “In the context of CHB, we believe that a multi-part approach that addresses HBV viral replication, HBsAg reduction and host T cell exhaustion may lead to either functional cure or effective chronic suppression for CHB patients. To date, our CAM program has shown dramatic reductions in viral DNA and RNA in CHB patients following 28 days of dosing in several CHB patient cohorts and dosing in additional cohorts is ongoing. We also plan to soon initiate a longer-term study evaluating ALG-000184 in combination with nucleos(t)ide analog therapy in HBeAg positive CHB. With respect to our siRNA program, ALG-125755, a potential best-in-class HBV siRNA, we remain on track to begin dosing in a Phase 1 study in healthy volunteers in the fourth quarter of this year. Meanwhile, on the NASH front, we are encouraged by initial clinical data for ALG-055009 in subjects with hyperlipidemia; additional data from this trial are expected to be released in the third quarter of this year.” Aligos’ ILC 2022 presentations, and their potential implications, are summarized below. Chronic hepatitis B (CHB) ALG-000184: Capsid assembly modulator (CAM)Poster number: SAT365Title: Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis BPresenter: Professor Man-Fung Yuen, MBBS, M.D., Ph.D., DSc, University of Hong Kong, Hong KongSummary: ALG-000184 is currently being evaluated in the ALG-000184-201 trial, a multi-part, double blind, randomized, placebo-controlled Phase 1 study (NCT04536337). Part 3 is ongoing and evaluating multiple cohorts (N=10/cohort; 8 active: 2 placebo) of currently not treated/treatment-naïve CHB subjects, who receive daily oral doses of ALG-000184 for 28 days, after which they are followed up for 8 weeks. Here, authors report preliminary safety, pharmacokinetic and antiviral data for CHB subjects enrolled in the following cohorts in Part 3: Cohort 1: 100 mg drug/placebo in HBeAg negative CHBCohort 2: 50 mg drug/placebo in HBeAg-negative CHBCohort 3: 10 mg drug/placebo in HBeAg-negative CHBCohort 4: 100 mg drug/placebo in HBeAg-positive CHB Key findings were as follows: Similar rapid declines in HBV DNA and HBV RNA were observed at all dose levels, regardless of HBeAg status. Among HBeAg-negative subjects, high rates of DNA and RNA reductions below the lower limit of quantification (LLOQ) were observed, with 100% of subjects